Page last updated: 2024-10-31

naftopidil and Urinary Tract Diseases

naftopidil has been researched along with Urinary Tract Diseases in 3 studies

Research Excerpts

ExcerptRelevanceReference
"To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)."9.14Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009)
"To evaluate treatment failure during a 4-year follow-up period after administration of naftopidil for patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in real-life clinical practice."7.74Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Hashimoto, J; Itoh, N; Masumori, N; Tsukamoto, T, 2007)
"To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)."5.14Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009)
"To evaluate treatment failure during a 4-year follow-up period after administration of naftopidil for patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in real-life clinical practice."3.74Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. ( Hashimoto, J; Itoh, N; Masumori, N; Tsukamoto, T, 2007)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yokoyama, T1
Uematsu, K1
Watanabe, T1
Sasaki, K1
Kumon, H1
Nagai, A1
Takeda, M1
Homma, Y1
Araki, I1
Kakizaki, H1
Yamanishi, T1
Yokota, T1
Gotoh, M1
Igawa, Y1
Seki, N1
Takei, M1
Yoshida, M1
Sugaya, K1
Nishizawa, O1
Masumori, N1
Hashimoto, J1
Itoh, N1
Tsukamoto, T1

Trials

2 trials available for naftopidil and Urinary Tract Diseases

ArticleYear
Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Scandinavian journal of urology and nephrology, 2009, Volume: 43, Issue:4

    Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Dose-Response Relationship, Drug; Drug Therapy, Comb

2009
Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
    BJU international, 2011, Volume: 108, Issue:1

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Epidemiologic Methods; Fema

2011

Other Studies

1 other study available for naftopidil and Urinary Tract Diseases

ArticleYear
Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Scandinavian journal of urology and nephrology, 2007, Volume: 41, Issue:5

    Topics: Adrenergic alpha-Antagonists; Aged; Humans; Kaplan-Meier Estimate; Male; Naphthalenes; Organ Size; P

2007